InterMune to net $228m in stock, note sale to pay down debt and finance Esbriet
This article was originally published in Scrip
InterMune will pay down debt and finance its pursuit of US FDA approval for Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) with $228.1 million in aggregate net proceeds from an offering of 13.5 million shares of common stock and the concurrent sale of 2.5% convertible senior notes worth $105 million in principal.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.